$56 Profit
CURLong Stock
F12B

Entry comments: Company announced that additional safety, efficacy and tolerability data from its exploratory Phase 2 clinical trial examining the efficacy of NSI-189. Entered because the stock was making higher lows, high volume, and I was comfortable with the entry.

Exit comments: I was working last night and could not sell into the strength around $3. Today I saw the dip, but I figured it would stabilize around 2.40 and go back up on Thursday but it dipped too far down for my comfort level. I lost a good amount of profit, and I didn't want to lose anymore so I exited.

000
DatePrice
Entry12/4/20171.98
Exit12/5/20172.202
  • Total Views52
  • Position Size250
  • Percentage11.21%
Copy and paste the following into your page or blog. If using WordPress, you must paste this in the HTML tab only:
Join now or log in to leave a comment